# 3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)

> **NCT05245292** · PHASE1 · COMPLETED · sponsor: **Rockefeller University** · enrollment: 28 (actual)

## Conditions studied

- Human Immunodeficiency Virus

## Interventions

- **DRUG:** 3BNC117-LS
- **DRUG:** 10-1074-LS
- **DRUG:** N803

## Key facts

- **NCT ID:** NCT05245292
- **Lead sponsor:** Rockefeller University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-07
- **Primary completion:** 2025-12-09
- **Final completion:** 2025-12-31
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05245292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05245292, "3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05245292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*